Articles
Study Results

Retatrutide and Fatty Liver (MASLD): What the Liver Fat Study Shows

The phase 2a liver fat study of retatrutide in people with obesity and fatty liver: how much liver fat fell, how many reached normal levels, and what the study could not show.

Written By
retaweightloss.com
Updated on
17 Nov 2026
Time to read
5 min read
Category
Study Results
Retatrutide and fatty liver: liver fat study results

Retatrutide and Fatty Liver (MASLD): What the Liver Fat Study Shows

The phase 2a liver fat study of retatrutide in people with obesity and fatty liver: how much liver fat fell, how many reached normal levels, and what the study could not show.

By
RetaWeightLoss.com
Created on:
02 Nov 2025
Updated on:
17 Nov 2026
Share this post

Retatrutide and Fatty Liver: The Short Answer

In the only published liver study of retatrutide so far, liver fat fell sharply. Among 98 people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD, previously called NAFLD), liver fat fell by up to 82.4% after 24 weeks on 12 mg, compared with a 0.3% increase on placebo, and 86% of people on that dose reached a normal liver fat level, below 5%. At 48 weeks, 93% on 12 mg were below that level.

The study measured liver fat only. It did not test whether retatrutide reverses liver inflammation or scarring, and retatrutide is not approved for fatty liver disease or any other use. Retatrutide's main Phase 3 obesity trial, TRIUMPH-1, did not measure liver fat. A large Phase 3 trial of liver outcomes is under way.

What MASLD and MASH Are

MASLD is a build-up of fat in the liver linked to metabolic conditions such as obesity and type 2 diabetes. In some people it progresses to metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), in which the fat is accompanied by inflammation and liver cell damage, and then to scarring (fibrosis) and, in some cases, cirrhosis. Reducing liver fat is an early step; preventing inflammation and fibrosis is what determines long-term liver outcomes.

Under the naming agreed by international liver societies in 2023, MASLD means fatty liver together with at least one metabolic risk factor, such as excess weight or high blood sugar, with alcohol use below set limits. People with metabolic risk factors who drink more than those limits are classed as MetALD, and heavier drinking points to alcohol-related liver disease. What is known about retatrutide and alcohol is covered in retatrutide and alcohol.

The Liver Fat Study

The study, published in Nature Medicine on June 10, 2024 (Sanyal and colleagues), was a substudy of retatrutide's 48-week Phase 2 obesity trial. It included 98 participants who had MASLD with at least 10% liver fat, measured by MRI proton density fat fraction (MRI-PDFF), an imaging method that estimates the share of the liver made up of fat. Participants were randomly assigned to weekly retatrutide 1 mg, 4 mg, 8 mg or 12 mg, or placebo. The primary result was the change in liver fat at 24 weeks.

GroupRelative change in liver fatReached normal liver fat (below 5%)
Retatrutide 1 mg −42.9% 27%
Retatrutide 4 mg −57.0% 52%
Retatrutide 8 mg −81.4% 79%
Retatrutide 12 mg −82.4% 86%
Placebo +0.3% 0%


All four doses reduced liver fat significantly more than placebo. The study was funded by the drug's developer, and several authors were employees of the company.

Results at 48 Weeks

The published paper also reports results at 48 weeks, which were first presented at the American Association for the Study of Liver Diseases meeting in November 2023. The effect held through 48 weeks, most clearly at the higher doses.

GroupRelative change in liver fatReached normal liver fat (below 5%)
Retatrutide 1 mg −51.3% Not shown here
Retatrutide 4 mg −59.0% Not shown here
Retatrutide 8 mg −81.7% 89%
Retatrutide 12 mg −86.0% 93%
Placebo −4.6% Not shown here


The lead investigator, Arun Sanyal, told HCPLive that by week 48, at the high dose, "93% of patients—lost so much fat in the liver that they were below the cutoff for having fatty liver disease."

Why Liver Fat Fell

The paper reports that the fall in liver fat was strongly associated with weight loss (correlation coefficients of 0.800 at 24 weeks and 0.739 at 48 weeks) and with reductions in waist size and abdominal fat, as well as with markers of better insulin sensitivity and fat metabolism. Liver fat reduction was close to its maximum in people who lost about 20% of their body weight. In the parent Phase 2 trial, average weight loss at 48 weeks was 24.2% on 12 mg.

Retatrutide also activates the glucagon receptor, but this study was not designed to separate any direct effect on the liver from the effect of weight loss.

What the Study Did Not Show

  • Inflammation and scarring. No liver biopsies were taken, so the study could not show whether MASH or fibrosis improved.
  • Long-term liver outcomes. It was too small and short to show effects on cirrhosis, liver failure or liver-related deaths.
  • Lasting effect. It did not report what happened to liver fat after treatment stopped (see weight regain after stopping retatrutide).
  • Phase 3 liver data. The main Phase 3 obesity trial did not measure liver fat; what it did report about the liver is covered in the next section.

What TRIUMPH-1 Reported About the Liver

TRIUMPH-1, retatrutide's main Phase 3 obesity trial, published in 2026, did not measure liver fat. According to its supplementary appendix, people with liver diseases other than fatty liver disease were excluded, while people with fatty liver disease could take part if their level of the liver enzyme ALT was below three times the upper limit of normal. Based on a review of medical history, 199 of the 2,339 participants (8.5%) had MASLD at the start. We found no separate results for this group in the paper or its appendix.

Average levels of the liver enzymes ALT and AST were within the normal range at the start and at week 80 in all four groups. Severe or serious liver disorders were reported in 3 people (0.5%) on 12 mg and in no one on the other doses or on placebo. The paper describes them as one case of acute hepatitis A, one case of liver injury from reduced blood flow, most likely due to dehydration linked to a bowel infection, and one rise in liver enzymes linked to a flare of gallstone disease. Safety data cover 80 weeks of treatment plus 4 weeks of follow-up.

SYNERGY-Outcomes: The Phase 3 Liver Trial

SYNERGY-Outcomes is a Phase 3 trial testing retatrutide and tirzepatide against placebo in about 4,500 adults with MASLD at higher risk of liver complications, defined by liver fat of at least 8%, a blood test of fibrosis (ELF score 9 to 10.8) and liver stiffness of 10 to under 20 kPa measured by ultrasound-based elastography. Its primary result is the time to a first major adverse liver outcome, such as progression to cirrhosis, complications of cirrhosis, liver transplant or death. It began in October 2025 and is listed as running until August 2032.

Approved Treatments for MASH

For context, two medicines are approved in the US for MASH with moderate to advanced fibrosis in adults without cirrhosis: resmetirom, granted accelerated approval on March 14, 2024, and semaglutide 2.4 mg, granted accelerated approval for this use on August 15, 2025, alongside diet and physical activity. How retatrutide compares with them has not been studied (see retatrutide vs tirzepatide vs semaglutide for weight loss).

What Is Still Unknown

  • Whether retatrutide improves liver inflammation and fibrosis, or reduces liver-related events.
  • Whether the liver fat reduction lasts after stopping.
  • How it compares with approved MASH treatments.
  • Its long-term safety in people with liver disease; its other reported effects are in retatrutide side effects.

Retatrutide is not approved for any use. Lilly has said it plans to submit it to the US Food and Drug Administration for obesity in the first quarter of 2027. Lilly says it is not on the market and that no one can legally sell it for human use, and it warns that illicit products "may contain unknown ingredients, harmful contaminants and impurities."

Sources

  • Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. Published June 10, 2024. DOI: 10.1038/s41591-024-03018-2.
  • VCU Health. News release on the retatrutide liver fat results presented at AASLD. November 13, 2023.
  • AASLD. Triple hormone receptor agonist retatrutide resolves steatosis in >85% of subjects with MASLD. The Liver Meeting abstract, November 2023.
  • HCPLive. Coverage of the retatrutide liver fat substudy at AASLD The Liver Meeting. November 2023.
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Supplementary Appendix, exclusion criteria and Tables S3 and S12. N Engl J Med. 2026.
  • Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556.
  • ClinicalTrials.gov. SYNERGY-Outcomes: tirzepatide and retatrutide in adults with MASLD. NCT07165028.
  • Lilly Medical. Is retatrutide being studied in patients with metabolic dysfunction-associated steatotic liver disease?
  • U.S. Food and Drug Administration. Accelerated approval of resmetirom for noncirrhotic NASH with moderate to advanced liver fibrosis. March 14, 2024.
  • U.S. Food and Drug Administration. Accelerated approval of semaglutide 2.4 mg for MASH with moderate to advanced fibrosis. August 15, 2025.
  • Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
  • Eli Lilly. What to know about retatrutide.

Medical Disclaimer: This article summarizes published research for general information only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

Does retatrutide reduce liver fat?

Yes, in its phase 2a study. Among 98 people with obesity and fatty liver disease, liver fat fell by 42.9% to 82.4% after 24 weeks depending on the dose, compared with a 0.3% increase on placebo. On 12 mg, 86% reached a normal liver fat level below 5%. Retatrutide is not approved for any use.

How much liver fat did people lose at 48 weeks?

In the published paper, liver fat fell by 81.7% on 8 mg and 86.0% on 12 mg at 48 weeks, and 89% and 93% of those groups reached normal liver fat levels below 5%. On the lower doses it fell by 51.3% and 59.0%, compared with 4.6% on placebo.

Can retatrutide treat MASH or liver fibrosis?

That has not been shown. The liver study measured fat with MRI only and took no biopsies, so it could not assess inflammation or scarring. SYNERGY-Outcomes, a Phase 3 trial in about 4,500 adults at higher risk of liver complications, is testing liver outcomes and is listed as running until 2032.

Is retatrutide approved for fatty liver disease?

No. Retatrutide is not approved for any use. Resmetirom and semaglutide 2.4 mg are approved in the US for MASH with moderate to advanced fibrosis in adults without cirrhosis. Retatrutide's developer plans to submit it to the FDA for obesity in the first quarter of 2027.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.